SpectraCure Q3 loss after tax narrows 85% to SEK 5.2 million

PUBT · 3d ago
SpectraCure Q3 loss after tax narrows 85% to SEK 5.2 million
  • SpectraCure’s third-quarter 2026 loss after tax narrowed 85% year over year to SEK 5.2 million.
  • Other operating income fell 85% to SEK 52,000, while operating cash outflow narrowed 57% to SEK 7.81 million year over year.
  • An August rights issue raised SEK 25.7 million before issuance costs and offsets.
  • At 12 months, four of five highest-dose relapse-study patients maintained low PSA levels and showed no tumors on MRI.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SpectraCure AB (publ) published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.